{"organizations": [], "uuid": "78feae7bdb5b45bb85349ad4cfb93920ef164959", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-adamas-announces-first-patient-enr/brief-adamas-announces-first-patient-enrolled-in-phase-3-trial-of-ads-5102-in-multiple-sclerosis-patients-with-walking-impairment-idUSASC09UQ5", "country": "US", "domain_rank": 408, "title": "BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-03T16:16:00.000+03:00", "replies_count": 0, "uuid": "78feae7bdb5b45bb85349ad4cfb93920ef164959"}, "author": "", "url": "https://www.reuters.com/article/brief-adamas-announces-first-patient-enr/brief-adamas-announces-first-patient-enrolled-in-phase-3-trial-of-ads-5102-in-multiple-sclerosis-patients-with-walking-impairment-idUSASC09UQ5", "ord_in_thread": 0, "title": "BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "adamas pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 3, 2018 / 1:17 PM / in 14 minutes BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment Reuters Staff \nApril 3 (Reuters) - Adamas Pharmaceuticals Inc: \n* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon:  ", "external_links": [], "published": "2018-04-03T16:16:00.000+03:00", "crawled": "2018-04-03T16:39:52.046+03:00", "highlightTitle": ""}